These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33030641)

  • 21. The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration.
    Karloski E; Dudley B; Diergaarde B; Blanco A; Everett JN; Levinson E; Rangarajan T; Stanich PP; Childers K; Brown S; Drogan C; Cavestro GM; Gordon K; Singh A; Simeone DM; Reich H; Kastrinos F; Zakalik D; Hampel H; Pearlman R; Gordon OK; Kupfer SS; Puzzono M; Zuppardo RA; Brand RE
    Cancer; 2024 Oct; 130(19):3297-3304. PubMed ID: 38809542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Feasibility of targeted cascade genetic testing in the family members of BRCA1/2 gene pathogenic variant/likely pathogenic variant carriers.
    Lee J; Ham JY; Park HY; Jung JH; Kim WW; Kang B; Chae YS; Lee SJ; Lee IH; Lee NY
    Sci Rep; 2022 Feb; 12(1):1842. PubMed ID: 35115620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
    Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes.
    Wei G; Teng M; Rosa M; Wang X
    Breast Cancer Res; 2022 Feb; 24(1):11. PubMed ID: 35135604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.
    Reiner AS; Robson ME; Mellemkjær L; Tischkowitz M; John EM; Lynch CF; Brooks JD; Boice JD; Knight JA; Teraoka SN; Liang X; Woods M; Shen R; Shore RE; Stram DO; Thomas DC; Malone KE; Bernstein L; Riaz N; Woodward W; Powell S; Goldgar D; Concannon P; ; Bernstein JL
    J Natl Cancer Inst; 2020 Dec; 112(12):1275-1279. PubMed ID: 32119081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.
    Bychkovsky BL; Agaoglu NB; Horton C; Zhou J; Yussuf A; Hemyari P; Richardson ME; Young C; LaDuca H; McGuinness DL; Scheib R; Garber JE; Rana HQ
    JAMA Oncol; 2022 Nov; 8(11):1598-1606. PubMed ID: 36136322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
    Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
    Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing.
    Sutcliffe EG; Stettner AR; Miller SA; Solomon SR; Marshall ML; Roberts ME; Susswein LR; Arvai KJ; Klein RT; Murphy PD; Hruska KS
    Cancer Genet; 2020 Aug; 246-247():12-17. PubMed ID: 32805687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results from London Regional Clinical Genetics services over a 5-year period on germline
    Garrett A; Talukdar S; Izatt L; Brady AF; Whyte S; Josephs KS; Shanmugasundaram M; Guillemot LS; Vakili D; Ey S; Ahmed M
    J Med Genet; 2022 Jun; 59(6):554-558. PubMed ID: 34266904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
    Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.
    Suspitsin EN; Yanus GA; Sokolenko AP; Yatsuk OS; Zaitseva OA; Bessonov AA; Ivantsov AO; Heinstein VA; Klimashevskiy VF; Togo AV; Imyanitov EN
    Med Oncol; 2014 Feb; 31(2):828. PubMed ID: 24415413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.
    Stolarova L; Kleiblova P; Zemankova P; Stastna B; Janatova M; Soukupova J; Achatz MI; Ambrosone C; Apostolou P; Arun BK; Auer P; Barnard M; Bertelsen B; ; Blok MJ; Boddicker N; Brunet J; Burnside ES; Calvello M; Campbell I; Chan SH; Chen F; Chiang JB; Coppa A; Cortesi L; Crujeiras-González A; ; De Leeneer K; De Putter R; DePersia A; Devereux L; Domchek S; Efremidis A; Engel C; Ernst C; Evans DGR; Feliubadaló L; Fostira F; Fuentes-Ríos O; Gómez-García EB; González S; Haiman C; Hansen TVO; Hauke J; Hodge J; Hu C; Huang H; Ishak NDB; Iwasaki Y; Konstantopoulou I; Kraft P; Lacey J; Lázaro C; Li N; Lim WK; Lindstrom S; Lori A; Martinez E; Martins A; Matsuda K; Matullo G; McInerny S; Michailidou K; Montagna M; Monteiro ANA; Mori L; Nathanson K; Neuhausen SL; Nevanlinna H; Olson JE; Palmer J; Pasini B; Patel A; Piane M; Poppe B; Radice P; Renieri A; Resta N; Richardson ME; Rosseel T; Ruddy KJ; Santamariña M; Dos Santos ES; Teras L; Toland AE; Trentham-Dietz A; Vachon CM; Volk AE; Weber-Lassalle N; Weitzel JN; Wiesmuller L; Winham S; Yadav S; Yannoukakos D; Yao S; Zampiga V; Zethoven M; Zhang ZW; Zima T; Spurdle AB; Vega A; Rossing M; Del Valle J; De Nicolo A; Hahnen E; Claes KBM; Ngeow J; Momozawa Y; James PA; Couch FJ; Macurek L; Kleibl Z
    Clin Cancer Res; 2023 Aug; 29(16):3037-3050. PubMed ID: 37449874
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas.
    De Sousa SMC; McCormack A; Orsmond A; Shen A; Yates CJ; Clifton-Bligh R; Santoreneos S; King J; Feng J; Toubia J; Torpy DJ; Scott HS
    J Clin Endocrinol Metab; 2024 Oct; 109(11):2720-2728. PubMed ID: 38651569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline pathogenic variant spectrum in 25 cancer susceptibility genes in Turkish breast and colorectal cancer patients and elderly controls.
    Akcay IM; Celik E; Agaoglu NB; Alkurt G; Kizilboga Akgun T; Yildiz J; Enc F; Kir G; Canbek S; Kilic A; Zemheri E; Ezberci F; Ozcelik M; Dinler Doganay G; Doganay L
    Int J Cancer; 2021 Jan; 148(2):285-295. PubMed ID: 32658311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: a case report.
    Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Kocdor MA; Nasioulas G
    BMC Med Genet; 2019 Jul; 20(1):131. PubMed ID: 31349801
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families.
    Schreurs MAC; Ramón Y Cajal T; Adank MA; Collée JM; Hollestelle A; van Rooij J; Schmidt MK; Hooning MJ
    Breast; 2024 Feb; 73():103611. PubMed ID: 38039887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.